Lantern Pharma's LP-184 Gets EMA Nod for Bladder Cancer Trial

Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, has announced that the European Medicines Agency (EMA) has cleared a Phase 1b/2 clinical trial for its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. This biomarker-guided study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients who have progressed on or are ineligible for current standard-of-care therapies. Patient selection will be based on PTGR1 overexpression and DNA-damage-repair deficiency, utilizing Lantern's proprietary RADR(R) platform to advance its AI-driven precision oncology strategy. The trial marks a significant step in expanding LP-184's potential beyond earlier indications, including pediatric CNS cancers being developed through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.

Lantern Pharma Inc. is a clinical-stage precision oncology company leveraging AI and machine learning to transform cancer therapy development. Its pipeline includes LP-284, targeting hematologic and solid tumors, and LP-300, a cisplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker lung adenocarcinoma. Additionally, the company's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research tool, generating a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. Investors can find the latest news and updates on Lantern Pharma at https://ibn.fm/LTRN.

This news was disseminated by BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release services, social media distribution, and tailored corporate communications. By cutting through information overload, BioMedWire helps clients reach a wide audience of investors, influencers, and the public.